Data Sheet 1_Active layer and permafrost microbial community coalescence increases soil activity and diversity in mixed communities compared to permafrost alone.docx by Stacey J. Doherty (6629561)

“…Microbial communities undergo significant compositional and functional shifts as permafrost thaws. …”

Data Sheet 1_In vivo profiling of the PE/PPE proteins of Mycobacterium tuberculosis reveals diverse contributions to virulence.pdf by Benjamin Koleske (11581641)

“…In all, 27 of the 87 mutants showed significant reductions in percent population prevalence in the lung over 3 weeks. …”

Table 2_Adherence to recombinant human growth hormone therapy in children: influencing factors and clinical implications.xlsx by Wenjing Chang (8334480)

“…However, non-adherence remains a significant challenge, affecting treatment efficacy and patient prognosis. …”

Supplementary file 1_Clinical features of benign paroxysmal positional vertigo in the elderly.docx by Ran Zhou (1450756)

“…The elderly group had significantly higher median scores in the DHI impact than the middle-aged group (24 vs. 16, p = 0.008). …”

Table 1_Adherence to recombinant human growth hormone therapy in children: influencing factors and clinical implications.xlsx by Wenjing Chang (8334480)

“…However, non-adherence remains a significant challenge, affecting treatment efficacy and patient prognosis. …”

Table 1_In vivo profiling of the PE/PPE proteins of Mycobacterium tuberculosis reveals diverse contributions to virulence.xlsx by Benjamin Koleske (11581641)

“…In all, 27 of the 87 mutants showed significant reductions in percent population prevalence in the lung over 3 weeks. …”

Supplementary file 1_Causative organisms of urinary tract infections and their drug sensitivity: an analysis from various aspects.docx by Xinwei Li (430518)

“…Comparing the distribution of causative organisms and drug sensitivity between 2022 and 2023, we found that the proportion of E. coli and Proteus mirabilis have increased significantly (p = 0.0066 and p = 0.0003, respectively), while the proportion of Enterococcus faecium have decreased significantly (p = 0.0419). …”

Supplementary file 1_Use of erythromycin and metoclopramide in hospitalized dogs: a multicenter historical cohort study.docx by Ee Fung Teo (21181196)

“…There were also significant differences in prokinetic use between institutions.…”

Supplementary file 2_Use of erythromycin and metoclopramide in hospitalized dogs: a multicenter historical cohort study.pdf by Ee Fung Teo (21181196)

“…There were also significant differences in prokinetic use between institutions.…”

Data Sheet 1_The impact of landscape patterns on surface runoff in the central urban area of Chengdu.docx by Ying Kang (2503126)

“…When the proportions of farmland and forestland were low, their effectiveness in reducing runoff decreased with increasing rainfall intensity. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”